Alterations in dopamine system and in its connectivity with serotonin in a rat model of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Dopamine pathways alterations are reported in Alzheimer’s disease. However, it is difficult in humans to establish when these deficits appear and their impact in the course of Alzheimer’s disease. In the TgF344-Alzheimer’s disease rat model at the age of 6 months, we showed a reduction in in vivo release of striatal dopamine due to serotonin 5HT2A-receptor blockade, in the absence of alterations in 5HT2A-receptor binding, suggesting a reduction in 5HT2A-receptor-dopamine system connectivity. In addition, a functional hypersensitivity of postsynaptic dopamine D2-receptors and D2-autoreceptors was also reported without any change in D2-receptor density and in the absence of amyloid plaques or overexpression of the 18 kDa translocator protein (an inflammatory marker) in areas of the dopamine system. Citalopram, a selective serotonin reuptake inhibitor, induced functional 5HT2A-receptor−D2-receptor connectivity changes but had no effect on D2-autoreceptor hypersensitivity. In older rats, dopamine cell bodies overexpressed translocator protein and dopamine projection sites accumulated amyloid. Interestingly, the 5HT2A-receptor density is decreased in the accumbens subdivisions and the substantia nigra pars compacta. This reduction in the striatum is related to the astrocytic expression of 5HT2A-receptor. Our results indicate that both serotonin/dopamine connectivity and dopamine signalling pathways are dysregulated and potentially represent novel early diagnostic and therapeutic avenues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nobili, A., Latagliata, E. C., Viscomi, M. T., Cavallucci, V., Cutuli, D., Giacovazzo, G., Krashia, P., Rizzo, F. R., Marino, R., Federici, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms14727 · Cited by 514 · cited 2×
“3C) [two-way ANOVA, treatment group interaction: F(4,53) 1⁄4 3.”
MethodBäckman, L., Lindenberger, U., Li, S.-C., & Nyberg, L. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.12.008 · Cited by 414
Dopamine-Evoked Synaptic Regulation in the Nucleus Accumbens Requires Astrocyte Activity
Corkrum, M., Covelo, A., Lines, J., Bellocchio, L., Pisansky, M., Loke, K., Quintana, R., Rothwell, P. E., Lujan, R., Marsicano, G., et al. (2020) · Neuron · doi:10.1016/j.neuron.2019.12.026 · Cited by 327
Rorabaugh, J. M., Chalermpalanupap, T., Botz-Zapp, C. A., Fu, V. M., Lembeck, N. A., Cohen, R. M., & Weinshenker, D. (2017) · Brain · doi:10.1093/brain/awx232 · Cited by 227
Serotonin stimulates secretion of exosomes from microglia cells
Glebov, K., Löchner, M., Jabs, R., Lau, T., Merkel, O., Schloss, P., Steinhäuser, C., & Walter, J. (2015) · Glia · doi:10.1002/glia.22772 · Cited by 221
Mitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer’s Disease
Guo, L., Tian, J., & Du, H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160702 · Cited by 211
Bartels, C., Wagner, M., Wolfsgruber, S., Ehrenreich, H., Schneider, A., & Initiative, F. T. A. D. N. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040404 · Cited by 202
Cellular localization of serotonin2A (5HT2A) receptors in the rat brain
Xu, T., & Pandey, S. C. (2000) · Brain Research Bulletin · doi:10.1016/s0361-9230(99)00278-6 · Cited by 194
Citalopram counteracts depressive-like symptoms evoked by chronic social stress in rats
Rygula, R., Abumaria, N., Flügge, G., Hiemke, C., Fuchs, E., Rüther, E., & Havemann-Reinecke, U. (2006) · Behavioural Pharmacology · doi:10.1097/01.fbp.0000186631.53851.71 · Cited by 104
Barr, A. M., Lehmann-Masten, V., Paulus, M., Gainetdinov, R. R., Caron, M. G., & Geyer, M. A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300343 · Cited by 103
Imaging of the 5-HT2A system: age-, gender-, and Alzheimer’s disease-related findings
Versijpt, J., Van Laere, K. J., Dumont, F., Decoo, D., Vandecapelle, M., Santens, P., Goethals, I., Audenaert, K., Slegers, G., Dierckx, R. A., et al. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00137-9 · Cited by 102
Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease
Reeves, S., Brown, R., Howard, R., & Grasby, P. (2009) · Neurology · doi:10.1212/01.wnl.0000341932.21961.f3 · Cited by 98
Cordella, A., Krashia, P., Nobili, A., Pignataro, A., La Barbera, L., Viscomi, M. T., Valzania, A., Keller, F., Ammassari-Teule, M., Mercuri, N. B., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.05.006 · Cited by 82
Voorhees, J. R., Remy, M. T., Cintrón-Pérez, C. J., El Rassi, E., Khan, M. Z., Dutca, L. M., Yin, T. C., McDaniel, L. N., Williams, N. S., Brat, D. J., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.023 · Cited by 78
Alzheimer’s Disease: The Alternative Serotonergic Hypothesis of Cognitive Decline
Vakalopoulos, C. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170364 · Cited by 34
Cited by
Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer’s disease
Eteleeb, A. M., Novotny, B. C., Tarraga, C. S., Sohn, C., Dhungel, E., Brase, L., Nallapu, A., Buss, J., Farias, F., Bergmann, K., et al. (2024) · PLOS Biology · doi:10.1371/journal.pbio.3002607 · Cited by 64
Cai, X., Wu, M., Zhang, Z., Liu, H., Huang, S., Song, J., Ren, S., & Huang, Y. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14200 · Cited by 28
Alzheimer’s disease: from early pathogenesis to novel therapeutic approaches
Prajapati, S. K., Pathak, A., & Samaiya, P. K. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01389-6 · Cited by 21
Metadata
- Authors
- Ceyzériat, K., Gloria, Y., Tsartsalis, S., Fossey, C., Cailly, T., Fabis, F., Millet, P., & Tournier, B. B.
- Venue
- Brain Communications
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-03-10
- Volume
- 3
- Issue
- 2
- Pages
- fcab029-fcab029
- ISSN
- 2632-1297 (ISSN-L)
- OpenAlex
- W3139009603
- Cited by
- 47
- References
- 15
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.